Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma

Phase 1

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2015-07-23

Lead Sponsor: University Health Network, Toronto

Registration Number: NCT00045513

Locations: 🇨🇦
Princess Margaret Hospital at University Health Network, Toronto, Ontario, Canada
🇨🇦
McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
London Health Sciences Centre, London, Ontario, Canada

UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia

Phase 1

Completed

Conditions: Lymphoma
Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-29

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00019838

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

Phase 2

Completed

Conditions: Hematologic Neoplasms

Interventions: Procedure: Apheresis
Procedure: Stem cell transplantation
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Methotrexate
Drug: Cyclosporine

First Posted Date: 2003-01-08

Last Posted Date: 2021-09-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 62

Registration Number: NCT00051311

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis

Phase 2

Completed

Conditions: Psoriasis
Arthritis, Psoriatic

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Target Recruit Count: 20

Registration Number: NCT00001422

Locations: 🇺🇸
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Bethesda, Maryland, United States

Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy

Phase 2

Completed

Conditions: Arthritis, Rheumatoid
Synovitis

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Target Recruit Count: 40

Registration Number: NCT00001677

Locations: 🇺🇸
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Bethesda, Maryland, United States

Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer

Phase 1

Terminated

Conditions: Breast Neoplasms
Metastases, Neoplasm

First Posted Date: 2002-11-11

Last Posted Date: 2012-04-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT00048893

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies

Phase 1

Completed

Conditions: Lymphoma
Leukemia

Interventions: Drug: Zevalin Radioimmunotherapy
Drug: Rituximab
Drug: Fludarabine
Drug: Cyclophosphamide
Procedure: Allogeneic Stem Cell Transplantation

First Posted Date: 2002-11-08

Last Posted Date: 2013-06-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 70

Registration Number: NCT00048737

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H

Phase 1

Completed

Conditions: Myelodysplastic Disorders
Leukemia
Multiple Myeloma
Plasma Cell Dyscrasia
Lymphoproliferative Disorders

First Posted Date: 2002-11-01

Last Posted Date: 2020-01-18

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 40

Registration Number: NCT00048412

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
The Methodist Hospital, Houston, Texas, United States

Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H

Phase 1

Terminated

Conditions: Graft Failure

First Posted Date: 2002-11-01

Last Posted Date: 2020-01-18

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 40

Registration Number: NCT00048399

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
The Methodist Hospital, Houston, Texas, United States

Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas

Phase 2

Completed

Conditions: Sarcoma

Interventions: Drug: F-18 Fluorodeoxyglucose
Biological: therapeutic allogeneic lymphocytes
Procedure: Peripheral Blood Stem Cell donation
Drug: cyclophosphamide
Drug: cyclosporine
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: fludarabine phosphate
Drug: melphalan
Drug: prednisone
Drug: sirolimus
Drug: tacrolimus
Drug: vincristine sulfate
Procedure: peripheral blood stem cell transplantation
Drug: Filgrastim

First Posted Date: 2002-08-16

Last Posted Date: 2017-05-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00043979

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy